Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Wirden

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|September 15, 2004
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II studyChristine Katlama, Jade Ghosn, Roland Tubiana, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Clinically relevant genotype interpretation of resistance to didanosineAnne-Geneviève Marcelin, Philippe Flandre, Juliette Pavie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2025
Consequences of stopping antiretroviral treatment in a persistently seronegative individual infected with HIV-1Marc Wirden, Amelie Guihot, Agnes Gautheret-Dejean, et al.
AIDS (London, England)|December 27, 2018
Caution is needed in interpreting HIV transmission chains by ultradeep sequencingEve Todesco, Marc Wirden, Ruxandra Calin, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 9, 2012
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infectionDavid Boutolleau, Ana Canestri, Sonia Burrel, et al.
AIDS (London, England)|March 3, 2006
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitorsBénédicte Roquebert, Isabelle Malet, Marc Wirden, et al.
Journal of Clinical Microbiology|July 17, 2023
Are Confirmatory Assays Reliable for HIV-1/HIV-2 Infection Differentiation? A Multicenter StudyVincent Guiraud, Jonathan Bocobza, Marion Desmonet, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 2009
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drugMarc Wirden, Anne Simon, Luminita Schneider, et al.
AIDS (London, England)|December 30, 2025
Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimensAnne-Geneviève Marcelin, Cathia Soulie, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2015
Combination of two pathways involved in raltegravir resistance confers dolutegravir resistanceIsabelle Malet, Eloise Thierry, Marc Wirden, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|September 15, 2004
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II studyChristine Katlama, Jade Ghosn, Roland Tubiana, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Clinically relevant genotype interpretation of resistance to didanosineAnne-Geneviève Marcelin, Philippe Flandre, Juliette Pavie, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2025
Consequences of stopping antiretroviral treatment in a persistently seronegative individual infected with HIV-1Marc Wirden, Amelie Guihot, Agnes Gautheret-Dejean, et al.
AIDS (London, England)|December 27, 2018
Caution is needed in interpreting HIV transmission chains by ultradeep sequencingEve Todesco, Marc Wirden, Ruxandra Calin, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 9, 2012
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infectionDavid Boutolleau, Ana Canestri, Sonia Burrel, et al.
AIDS (London, England)|March 3, 2006
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitorsBénédicte Roquebert, Isabelle Malet, Marc Wirden, et al.
Journal of Clinical Microbiology|July 17, 2023
Are Confirmatory Assays Reliable for HIV-1/HIV-2 Infection Differentiation? A Multicenter StudyVincent Guiraud, Jonathan Bocobza, Marion Desmonet, et al.
The Journal of Antimicrobial Chemotherapy|September 1, 2009
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drugMarc Wirden, Anne Simon, Luminita Schneider, et al.
AIDS (London, England)|December 30, 2025
Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimensAnne-Geneviève Marcelin, Cathia Soulie, Marc Wirden, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2015
Combination of two pathways involved in raltegravir resistance confers dolutegravir resistanceIsabelle Malet, Eloise Thierry, Marc Wirden, et al.
Pageof 10